← Back to Screener
4D Molecular Therapeutics, Inc. Common Stock (FDMT)
Price$10.49
Favorite Metrics
Price vs S&P 500 (26W)9.12%
Price vs S&P 500 (4W)12.34%
Market Capitalization$535.53M
All Metrics
Book Value / Share (Quarterly)$8.78
P/TBV (Annual)2.28x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)200.82%
Cash Flow / Share (Quarterly)$-1.90
Price vs S&P 500 (YTD)35.73%
Net Profit Margin (TTM)-164.43%
EPS (TTM)$-2.55
10-Day Avg Trading Volume0.75M
EPS Excl Extra (TTM)$-2.55
Revenue Growth (5Y)44.32%
EPS (Annual)$-2.42
ROI (Annual)-27.71%
Net Profit Margin (5Y Avg)-87851.79%
Cash / Share (Quarterly)$6.99
Revenue Growth QoQ (YoY)8508900.00%
ROA (Last FY)-24.72%
Revenue Growth TTM (YoY)230194.59%
EBITD / Share (TTM)$-2.67
ROE (5Y Avg)-32.16%
Operating Margin (TTM)-187.24%
Cash Flow / Share (Annual)$-1.90
P/B Ratio1.06x
P/B Ratio (Quarterly)0.85x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)5.58x
ROA (TTM)-28.30%
EPS Incl Extra (Annual)$-2.42
Current Ratio (Annual)9.39x
Quick Ratio (Quarterly)9.15x
3-Month Avg Trading Volume0.87M
52-Week Price Return260.48%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$7.72
P/S Ratio (Annual)6.28x
Asset Turnover (Annual)0.15x
52-Week High$12.34
Operating Margin (5Y Avg)-102464.20%
EPS Excl Extra (Annual)$-2.42
CapEx CAGR (5Y)-11.73%
26-Week Price Return17.87%
Quick Ratio (Annual)9.15x
13-Week Price Return19.75%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)9.39x
Enterprise Value$475.289
Revenue / Share Growth (5Y)23.59%
Asset Turnover (TTM)0.17x
Book Value / Share Growth (5Y)-1.78%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-164.43%
Cash / Share (Annual)$6.99
3-Month Return Std Dev72.73%
Net Income / Employee (TTM)$-1
ROE (Last FY)-27.71%
EPS Basic Excl Extra (Annual)$-2.42
Receivables Turnover (TTM)4.92x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.55
Receivables Turnover (Annual)24.05x
ROI (TTM)-31.75%
P/S Ratio (TTM)6.28x
Pretax Margin (5Y Avg)-87851.79%
Revenue / Share (Annual)$1.47
Tangible BV / Share (Annual)$7.09
Price vs S&P 500 (52W)225.39%
Year-to-Date Return39.87%
5-Day Price Return4.48%
EPS Normalized (Annual)$-2.42
ROA (5Y Avg)-28.87%
Net Profit Margin (Annual)-164.43%
Month-to-Date Return12.67%
Cash Flow / Share (TTM)$-2.52
EBITD / Share (Annual)$-2.67
Operating Margin (Annual)-187.24%
ROI (5Y Avg)-32.16%
EPS Basic Excl Extra (TTM)$-2.55
P/TBV (Quarterly)1.60x
P/B Ratio (Annual)0.85x
Pretax Margin (TTM)-164.43%
Book Value / Share (Annual)$8.78
Price vs S&P 500 (13W)16.88%
Beta2.95x
P/FCF (Annual)69.82x
Revenue / Share (TTM)$1.33
ROE (TTM)-31.75%
52-Week Low$2.88
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.12
4.12
4.12
4.12
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
FDMT4D Molecular Therapeutics, Inc. Common Stock | 6.28x | 230194.59% | — | — | $10.49 |
AMGNAmgen Inc | 5.21x | 9.95% | 73.30% | 2.93% | $355.30 |
GILDGilead Sciences Inc | 5.80x | 2.40% | 78.83% | 133.64% | $137.64 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $849.04 |
BNTXBioNTech SE American Depositary Share | 8.99x | -11.81% | 84.21% | — | $102.92 |
BIIBBiogen Inc. Common Stock | 2.63x | 2.22% | 75.69% | -18.77% | $177.35 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $53.72 |
NBIXNeurocrine Biosciences Inc | 4.68x | 21.45% | 98.18% | 2.31% | $133.25 |
EXELExelixis Inc | 5.02x | 6.85% | 96.39% | 31.10% | $44.89 |
TECHBio-Techne Corp. | 7.62x | 1.64% | 66.60% | -20.58% | $59.23 |
HALOHalozyme Therapeutics, Inc. | 5.88x | 37.55% | 83.62% | 22.89% | $69.29 |
About
4D Molecular Therapeutics is a clinical-stage gene therapy company developing novel treatments using evolved AAV vectors across three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company's pipeline includes multiple product candidates targeting retinal diseases, heart conditions, and pulmonary disorders, leveraging its proprietary vector technology designed for targeted delivery and efficacy. With programs spanning intravitreal, intravenous, and aerosol administration routes, 4D is advancing a diversified approach to gene therapy development.